Chronic Hepatitis B (CHB)
Conditions
Interventions
Chronic hepatitis B observation group:None
Sponsors
The Third Affiliated Hospital Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with chronic hepatitis B were treated with first-line drugs such as ETV, tenofovir fumarate (TDF) or tenofovir fumarate (TAF) or emitinofovir (TMF) monotherapy for more than 48 weeks, serum HBV DNA could be detected by sensitive qPCR (the lowest detection limit was 20 IU/mL or 10 IU/mL) , but the compliance was excluded. 2. The age is 18 ~ 60 years old (including 18,60 years old) , sex is not limited. 3. No restriction on HBeAg status. 4. For subjects with modified NAS regimen, only ETV + TDF, TAF + ETV, ETV + TMF, and Nas monotherapy were enrolled Nas plus interferon group: enrolled only one NAs plus Peg IFN a-2b or two NAs plus Peg IFN a-2b; unadjusted patients: still receiving the original monotherapy; 5.Compliant and willing to sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with decompensated cirrhosis or previous decompensated cirrhosis. 2.Use of interferon within 6 months; 3.Co-infection with other viruses, such as hepatitis A virus, Hepatitis C virus, hepatitis D virus, Hepatitis E virus, HIV; 4. In addition to hepatitis B accompanied by other serious physical and mental diseases, these include uncontrolled primary kidney, heart, lung, vascular, neurological, digestive, severe metabolic diseases (such as uncontrolled hyperthyroidism, severe complications of diabetes and adrenal diseases) , immunodeficiency, active or suspected malignant tumor or history of malignant tumor; 5.Those who were receiving corticosteroid, immunosuppressants, and chemotherapy drugs 6 months before enrollment. 6. Alcoholic liver disease, autoimmune liver disease and other liver diseases. 7. BMI > 28kg/m^2; 8. HBV drug-resistant patients; 9. Other conditions that the researchers consider unsuitable for enrollment; 10.In this study, first-line physicians determined patients' suitability for NAS and interferon therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantification of hepatitis B surface antigen; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quantification of hepatitis B virus;Hepatitis B e antigen; | — |
Countries
China
Contacts
Public ContactZhang Ka
The Third Affiliated Hospital Sun Yat-sen University
Outcome results
None listed